<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331093</url>
  </required_header>
  <id_info>
    <org_study_id>k2020033</org_study_id>
    <nct_id>NCT04331093</nct_id>
  </id_info>
  <brief_title>Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma</brief_title>
  <official_title>A Single-cencer,Phase II Study of Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Di Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Hospital of Jilin University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acral melanoma is a melanoma that affects acral areas of the skin, which is the most
      prevalent site of melanoma in non-Caucasians.Data in this subgroup is scarce.This study is to
      evalueate the efficiency and safety of Neoadjuvant SHR-1210 plus apatinib in this particular
      group,menawhile to determine the predictive value for efficiency of several biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a
      new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase
      inhibitor (TKI).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR</measure>
    <time_frame>3 months</time_frame>
    <description>Pathological complete response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>npCR</measure>
    <time_frame>3 months</time_frame>
    <description>Near pathological complete response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 months</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 Year RFS</measure>
    <time_frame>3 years</time_frame>
    <description>Recurrence free survival in 3 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acral Melanoma</condition>
  <arm_group>
    <arm_group_label>resectable stage III-IV Acral melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210+Apatinib</intervention_name>
    <description>Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg
Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression</description>
    <arm_group_label>resectable stage III-IV Acral melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18 to 75 years. 2. Clinically diagnosed or pathologically diagnosed, resectable stage
        III-IV Acral melanoma with at least one measurable lesion that has not been treated locally
        (according to RECISTv1.1, this measurable lesion is spiral CT (Or MRI scan with a long
        diameter ≥10mm or an enlarged lymph node with a short diameter ≥15mm), patients with
        metastasis can also be enrolled; 3. Have not received any anti-tumor medication before. 4.
        ECOG score is 0 or 1. 5. Tumor tissue specimens must be provided for genetic testing
        (preoperative biopsy / intraoperative tissue removal).

        6. Expected survival time ≥ 12 weeks. 7. The level of organ function must meet the
        following requirements (7 days before randomization):

          -  Peripheral blood: absolute neutrophil count (≥) 1.5 × 109 / L, platelet count (≥) 100
             × 109 // L, hemoglobin (Hb) ≥9g / dL (no blood transfusion within 14 days before
             detection);

               -  Liver: serum total bilirubin (≤) 1.5 × ULN, aspartate aminotransferase (AST) and
                  alanine aminotransferase (ALT) ≤ 3 × ULN (or AST, ALT ≤ 5 × ULN);

                    -  Serum creatinine ≤1.5 × ULN or endogenous creatinine clearance ≥50mL / min
                       (using Cockcroft-Gault formula); ④. International normalized ratio (INR) and
                       activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (only applicable to
                       patients who have not received anticoagulant therapy and received
                       anticoagulant therapy, and anticoagulant drugs should meet the treatment
                       requirements);

                       ⑤. Cardiac function is normal, that is, the result of ECG is normal or has
                       no clinical significance. Left ventricular ejection fraction (LVEF) of
                       cardiac ultrasound examination is&gt; 50%.

                       8. Women of childbearing age must have a negative pregnancy test within 7
                       days before treatment; males of reproductive capacity or women who are at
                       risk of pregnancy must use effective contraception throughout the study
                       period and continue contraception for 3 months after the end of treatment.

                       9. Can swallow pills normally. 10. Voluntarily participate in the research
                       and sign the informed consent form, with good compliance and willingness to
                       cooperate with the follow-up.

        Exclusion Criteria:

          1. Patients who have been treated with anti-PD-1, anti-PD-L1, VEGFRTKI;

          2. Patients who are participating or are participating in clinical studies of other drugs
             or treatments, within 4 weeks before enrollment (prior to randomization);

          3. Patients who received major surgery, vaccines, and systemic hormone therapy within 4
             weeks before the study began; and patients who received radiation therapy within 2
             weeks;

          4. In the past 3 years, other malignancies other than acral or mucosal melanoma, except
             for cured skin basal cell carcinoma, skin squamous cell carcinoma, early prostate
             cancer and cervical cancer;

          5. Receive hematopoietic stimulating factors (such as granulocyte colony stimulating
             factor (G-CSF) and erythropoietin) within 1 week before the start of the study.

          6. HIV positive test;

          7. Patients with active hepatitis B or C:

             ①. In the case of HBsAg or HBcAb positive, additional HBVDNA testing (results above
             the lower limit of detection specified by the study site).

             ②. In the case of HCV antibody positive, perform additional HCVRNA detection.

          8. Urine routine indicates urinary protein ≥ ++ and it has been confirmed that the amount
             of urinary protein in 24 hours is&gt; 1.0g;

          9. Suffering from high blood pressure and cannot be well controlled by antihypertensive
             drugs (systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg);

         10. Pleural effusion or ascites with clinical symptoms and symptomatic treatment;

         11. People with ocular shape and central nervous system (CNS) metastasis;

         12. Have a history of active tuberculosis;

         13. Have any uncontrollable clinical problems, including but not limited to:

             ①. Have autoimmune disease, or have a history of autoimmune disease or a syndrome
             requiring systemic treatment with steroids / immunosuppressants, such as pituitary
             inflammation, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism and thyroid
             Hypofunction

             ②. The following occurred within the first 6 months of randomization: 1) deep vein
             thrombosis or pulmonary embolism; 2) percutaneous coronary intervention, acute
             coronary syndrome, coronary artery bypass grafting; 3) cerebrovascular accident,
             Transient ischemic attack.

             ③. Other serious and uncontrolled companion diseases that may affect the compliance of
             the agreement or the interpretation of the results, including active opportunistic or
             progressive (severe) infection, uncontrolled diabetes, cardiovascular disease (graded
             by the New York Heart Association) System-defined grade III or IV heart failure, grade
             II heart block, myocardial infarction in the past 6 months, unstable arrhythmia or
             unstable angina, cerebral infarction in the past three months, etc.). Or lung disease
             (history of interstitial pneumonia, obstructive pulmonary disease, and symptomatic
             bronchospasm);

         14. Patients with any condition that affects swallowing the drug, and any condition that
             affects the absorption of the research product in vivo, including any type of
             gastrointestinal resection or surgery;

         15. Previous stem cell transplant or organ transplant;

         16. Women with childbearing potential or pregnant or lactating women with a positive serum
             or urine pregnancy test within 7 days before the start of treatment;

         17. Previously addicted to antipsychotic drugs, cannot be quit, or have a history of
             mental illness;

         18. Other serious, acute or chronic medical conditions or laboratory abnormalities may
             increase the risks associated with participating in the research or may interfere with
             the interpretation of the research results by investigators;

         19. Other conditions that the researchers consider to be non-compliant or not applicable
             to participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Di Wu, MD</last_name>
    <phone>13944888991</phone>
    <phone_ext>13944888991</phone_ext>
    <email>Wudi991202@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Di Wu, MD</last_name>
      <phone>13944888991</phone>
      <phone_ext>13944888991</phone_ext>
      <email>Wudi991202@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Hospital of Jilin University</investigator_affiliation>
    <investigator_full_name>Di Wu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

